CTRI/2024/04/064982尚未招募不适用
Evaluation of DSC-3 expression in triple negative breast cancer (TNBC)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- To evaluate the immunohistochemical expression of DSC3 in tumor blocks of patients with triple negative breast cancer and determine the cutoff levels of its expression for segregating patients with and without relapse in the discovery cohort
研究概览
简要总结
In this study we will assemble a discovery cohort of blocks from patients with TNBC who have or have not experienced relapse with a defined followup time.
A total of stage 1-3 TNBC patients will be selected, 35 with no relapse with atleast 2 years of follow and 15 patients with relapse at any time point after initial curative treatment.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Histopathological diagnosis of TNBC.
- •2.Patients who have undergone curative surgery (BCT or MRM) for breast cancer either after initial treatment or after neoadjuvant chemotherapy.
- •3.Either disease free survival from the time of diagnosis of atleast 2 years and no relapse OR relapse after initial curative treatment at any timepoint.
- •4.Initial clinical stage 1 to 3 disease.
- •5.Availability of the paraffin blocks of fulfilling the above criteria.
排除标准
- •1.Non availability of tumor tissue block.
- •2.No available survival data.
结局指标
主要结局
To evaluate the immunohistochemical expression of DSC3 in tumor blocks of patients with triple negative breast cancer and determine the cutoff levels of its expression for segregating patients with and without relapse in the discovery cohort
时间窗: 12 months
次要结局
- NA(NA)
研究者
Dr Sudeep Gupta
Tata Memorial Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial2023-507875-23-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting60
尚未招募
不适用
Prognostics Biomarker study in triple negative breast cancer patientCTRI/2024/11/076720Datta Meghe Institute of Higher Education and Research Wardha24
尚未招募
不适用
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBCNCT07332975University of Pittsburgh77
尚未招募
1 期
FMT in Triple Negative Breast Cancer Guided by ctDNABreast CancerNCT07292142Jewish General Hospital125
进行中（未招募）
不适用
VBC103 治疗晚期恶性实体瘤受试者的 I/IIa 期临床试验CTR20254758255